Skip to main content

Cytokinetics Value Stock - Dividend - Research Selection

Cytokinetics

ISIN: US23282W6057 , WKN: A1W1KK

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. The company\'s drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in phase III clinical trials in patients with heart failure; and reldesemtiv, a fast skeletal muscle activator, which is in two phase II clinical trials in patients with spinal muscular atrophy and amyotrophic lateral sclerosis. It also develops reldesemtiv that is in phase II clinical trials in patients with chronic obstructive pulmonary disease, as well as in phase Ib clinical trials in elderly subjects with limited mobility. The company has strategic alliances with Astellas Pharma Inc. and Amgen Inc. The company was founded in 1997 and is headquartered in South San Francisco, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK) and CymaBay Therapeutics (CBAY)

2023-09-22
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Cytokinetics participates in a conference call with JPMorgan

2023-09-19
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Cytokinetics: Clinical Efficacy Isn't Enough For Success

2023-09-18
Cytokinetics' declining revenue and high R&D spend amplify financial risks, despite a $592.6M liquidity position and 14.6-month cash runway. Learn more on CYTK stock here.

EVP Research & Development Fady Malik Sells 2,500 Shares of Cytokinetics Inc

2023-09-15
On September 14, 2023, Fady Malik, the Executive Vice President of Research & Development at Cytokinetics Inc (NASDAQ:CYTK), sold 2,500 shares of the company.

Analysts Are Bullish on These Healthcare Stocks: Cytokinetics (CYTK), Alnylam Pharma (ALNY)

2023-09-14
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Insider Sell: Cytokinetics Inc's President & CEO Robert Blum Sells 12,500 Shares

2023-09-14
On September 13, 2023, Robert Blum, President & CEO of Cytokinetics Inc (NASDAQ:CYTK), sold 12,500 shares of the company.

Analysts Conflicted on These Healthcare Names: American Well (AMWL) and Cytokinetics (CYTK)

2023-09-13
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Mizuho Securities Remains a Buy on Cytokinetics (CYTK)

2023-09-12
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

10 Biotech Stocks with Biggest Upside

2023-09-09
In this article, we discuss 12 biotech stocks with biggest upside. If you want to skip our detailed discussion on the recent developments in the biotech industry, you can go directly to 5 Biotech Stocks with Biggest Upside. According to Precedence Research, the size of the biotechnology industry stood at $1.22 trillion at the end […]

The 3 Best Mid-Cap Stocks to Buy Now: September 2023

2023-09-07
Banking on the Goldilocks narrative, targeting the best mid-cap stocks centers mostly on balance. If you go the small-capitalization route, you’ll benefit from maximum upside potential. However, materializing said potential is a whole different ballgame. On the flip side, the blue chips offer a higher probability of success. Unfortunately, that success typically yields limited upside. So, what do you do, especially under this ambiguous market cycle? In my opinion, the best mid-cap stocks give yo